To include your compound in the COVID-19 Resource Center, submit it here.

HIV sales prop up Gilead’s 3Q as Yescarta misses estimates

Gilead leaned on its HIV franchise to meet the Street’s expectations on its 3Q19 results, as HCV sales continued to fall and the company’s high-profile cell therapy Yescarta missed revenue expectations.

Gilead Sciences Inc. (NASDAQ:GILD) reported non-GAAP EPS of $1.75 on revenues of $5.6 billion for

Read the full 459 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE